within Pharmacolibrary.Drugs.ATC.J;

model J01RA09
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.95,
    Cl             = 8 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,
    adminCount     = 1,
    Vd             = 0.1,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.011666666666666665,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Ofloxacin and ornidazole is a fixed-dose combination antibacterial and antiprotozoal medication used primarily for the treatment of mixed infections, including those involving anaerobic bacteria and protozoa, such as in gastrointestinal and gynecological infections. Ofloxacin is a fluoroquinolone antibiotic, while ornidazole is a nitroimidazole derivative. The combination is still used in some countries although not universally approved.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adult subjects based on individual drug characteristics, as no published population PK model or combination PK study for ofloxacin and ornidazole is available.</p><h4>References</h4><ol><li><p>Boeckh, M, Lode, H, Deppermann, KM, Grineisen, S, Shokry, F, Held, R, Wernicke, K, Koeppe, P, Wagner, J, &amp; Krasemann, C (1990). Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole. <i>Antimicrobial agents and chemotherapy</i> 34(12) 2407â€“2414. DOI:<a href=&quot;https://doi.org/10.1128/AAC.34.12.2407&quot;>10.1128/AAC.34.12.2407</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2088195/&quot;>https://pubmed.ncbi.nlm.nih.gov/2088195</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J01RA09;
